InSite is seeking marketing approval of BromSite in the United States. In its confirmatory Phase 3 clinical trials, BromSite achieved statistically significant superiority to vehicle in alleviating ocular
The amendment enhances MPP’s current licence by allowing South African manufacturers to join Indian and Chinese companies in developing generics for low- and middle-income countries. "We welcome the
The Phase 3 clinical trial program, known as COGNITIV SZ, is designed to assess the safety and efficacy of encenicline compared to placebo as a pro-cognitive therapy in
The double-blind, placebo-controlled clinical study is designed to evaluate the safety, tolerability, and clinical efficacy of asimadoline in patients with pruritus due to atopic dermatitis and is being
Under the agreement, Abbott will offer its HIV viral load tests – which monitor the amount of HIV in a person’s blood – at reduced prices to help
The patent covers the use of this therapeutic for treating dyskinesia associated with L-DOPA therapy in Parkinson’s disease. "This recent patent award will provide robust protection for MLR-1019
In addition, the company has received a notice of allowance of Canada Patent 2,665,783, which covers processes for making a broad range of amphoteric liposomes, including the SMARTICLES
The product candidate is developed for the indications of refractory and tophaceous gout, which result from elevated levels of uric acid within the body that cause debilitating pain
OM results in the painful inflammation and ulceration of the membranes lining the oral cavity, throat, and esophagus and is among the most frequently reported adverse events associated
Cyclosporine A, when administered systemically (Sandimmune, Neoral), is an effective treatment for psoriasis, atopic dermatitis, pemphigus vulgaris and other severe inflammatory dermatoses. Dr. Daniel Teper, the CEO of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.